# data[].attributes.body
NIH National Library of Medicine

Faden, J., & Citrome, L. (2020, November 9). Intravenous brexanolone for postpartum depression: What it is, how well does it work, and will it be used? Therapeutic advances in psychopharmacology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656877/

published Nov. 9, 2020

# data[].attributes.body
Zulresso (brexanolone) is manufactured by Sage Therapeutics

# data[].attributes.attachment_link.readable_text
What is ZULRESSO?

ZULRESSO ® is a prescription medicine used to treat Postpartum Depression in individuals 15 years and older.

It is not known if ZULRESSO is safe and effective in individuals less than 15 years of age.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ZULRESSO?
ZULRESSO can cause serious side effects, including:

Excessive sedation and sudden loss of consciousness. ZULRESSO may cause you to feel very sleepy (excessive sedation) or pass out (loss of consciousness). Your healthcare provider should check you for symptoms of excessive sleepiness every 2 hours while you are awake.

During your ZULRESSO infusion, tell your healthcare provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out. Your healthcare provider may lower your dose or stop the infusion until symptoms go away.

You must have a caregiver or family member with you to help care for your child(ren) during your ZULRESSO infusion.

Because of the risk of serious harm resulting from excessive sedation or sudden loss of consciousness, ZULRESSO is only available through a restricted program called the ZULRESSO REMS.

Before receiving ZULRESSO, tell your healthcare provider about all your medical conditions, including if you:

Drink alcohol

Have kidney problems

Are pregnant or think you may be pregnant. It is not known if ZULRESSO will harm your unborn baby.
There is a pregnancy registry for women who are exposed to ZULRESSO during pregnancy. The purpose of the registry is to collect information about the health of women exposed to ZULRESSO and their baby. If you become pregnant during treatment with ZULRESSO, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1‑844‑405‑6185 or visit https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/

Are breastfeeding or plan to breastfeed. ZULRESSO passes into breast milk. Talk to your healthcare provider about the risks and benefits of breastfeeding and about the best way to feed your baby while receiving ZULRESSO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

ZULRESSO and some medicines may interact with each other and cause serious side effects.

Especially tell your healthcare provider if you take other antidepressants, opioids, or Central Nervous System (CNS) depressants (such as benzodiazepines).

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. Your healthcare provider will decide if other medicines can be taken with ZULRESSO.

How will I receive ZULRESSO?

ZULRESSO is given to you by continuous intravenous (IV) infusion into your vein. The infusion will last for a total of 60 hours (2.5 days).

What should I avoid while receiving ZULRESSO?

ZULRESSO may make you feel dizzy and sleepy. Do not drive a car or do other dangerous activities after your ZULRESSO infusion until your feeling of sleepiness has completely gone away. See "What is the most important information I should know about ZULRESSO?"

Do not drink alcohol while receiving ZULRESSO.

What are the possible side effects of ZULRESSO?
ZULRESSO can cause serious side effects, including:

See "What is the most important information I should know about ZULRESSO?"

Increased risk of suicidal thoughts or actions. ZULRESSO and other antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger. Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions.

How can I watch for and try to prevent suicidal thoughts and actions?

Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.

Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings.

Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.

Tell your healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:

Attempts to commit suicide, thoughts about suicide or dying, new or worse depression, other unusual changes in behavior or mood.
The most common side effects of ZULRESSO include:

Sleepiness, dry mouth, passing out, flushing of the skin or face.

These are not all the side effects of ZULRESSO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please also see Full Prescribing Information including Boxed Warning and Medication Guide for ZULRESSO® and discuss any questions you may have with your healthcare provider.

# data[].attributes.attachment_link.title
Treat Postpartum Depression | ZULRESSO® (brexanolone) CIV

# data[].attributes.attachment_link.description
Learn about ZULRESSO®, an FDA-approved treatment for PPD in adults. See full Prescribing Information, Boxed Warning, and Important Safety Info.

# data[].attributes.body
https://www.youtube.com/watch?v=eshRnsJFIXA

# data[].attributes.attachment_link.title
Zulresso to relieve symptoms of postpartum depression

# data[].attributes.body
Brexanolone is the first medication approved by the US Food and Drug Administration for the treatment of postpartum depression.

It's a unique intravenous formulation of allopregnanolone, a neuroactive steroid that modulates GABA receptors in the brain, which can help alleviate mood symptoms.

Administration: Zulresso is given as a continuous intravenous infusion over a 60-hour period, typically in a healthcare setting.

Efficacy: Clinical studies have shown that it can provide rapid relief from PPD symptoms, often within 24 hours of starting treatment.

Refences

Faden, J., & Citrome, L. (2020, November 9). Intravenous brexanolone for postpartum depression: What it is, how well does it work, and will it be used? Therapeutic advances in psychopharmacology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656877/

OpenAI. (2023). ChatGPT (v. GPT-4). https://www.openai.com/chatgpt

# data[].attributes.attachment_link.title
Zulresso: New Medication For Postpartum Depression | What You Need To Know

# data[].attributes.body
Pros:

1. Rapid Relief: Many patients experience significant improvement in symptoms within 24 hours, which is faster than traditional antidepressants.

2. Targeted Treatment: Specifically approved for postpartum depression, addressing a significant need in maternal mental health.

3. Unique Mechanism: Works through the modulation of GABA receptors, which can provide a different approach compared to standard antidepressants.

4. In-Hospital Administration: The monitored setting can ensure safety and immediate management of any side effects.

# data[].attributes.body
Intravenous Administration: Requires a 60-hour continuous infusion, which can be inconvenient and requires hospitalization or close monitoring.

Cost: It can be expensive, and insurance coverage may vary.

Side Effects: Common side effects include sedation, dizziness, and potential infusion site reactions

# data[].attributes.body
Post partum depression has far-reaching consequences. Mothers with PPD have an increased risk of morbidity and mortality. Per Faden and Citrome (2020), "afflicted mothers show an overall decrease in attention to infant needs, causing a delay in the child’s height, weight, and emotional and behavioral development. Disrupted and insufficient mother–child attunement can also result in impaired child social and interpersonal functioning."

This treatment is an exciting innovation with the potential to make huge strides toward improving the quality of life for women and families.

Reference

Faden, J., & Citrome, L. (2020, November 9). Intravenous brexanolone for postpartum depression: What it is, how well does it work, and will it be used? Therapeutic advances in psychopharmacology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656877/

# data[].attributes.body
My clifton strengths are maximizer, harmony, connectedness, developer, adaptability.

As a developer, I can spot the signs of small improvement and derive satisfaction from these
improvements. I encourage myself and others to look at what is going right, instead of just what is going wrong. That helps you to proceed and stay optimistic even when growth is slow.

I think my strength of maximizer would be helpful in implementing this innovation. I worked with postpartum women for many years, and had postpartum depression myself. This is a cause I feel passionately about and believe that it has the potential transform the lives of women and families.

# data[].attributes.body
Faden, J., & Citrome, L. (2020, November 9). Intravenous brexanolone for postpartum depression: What it is, how well does it work, and will it be used? Therapeutic advances in psychopharmacology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656877/

OpenAI. (2023). ChatGPT (v. GPT-4). https://www.openai.com/chatgpt

# data[].attributes.body
I choose

Andrew (Activator)- he is a self-starter and fearless

Brandon (belief)- he is passionate and steadfast

Cindy (connectedness)- she is always looking at the big picture

David (deliberative)- he identifies risks and plans for the unexpected

Isaac (ideation)- he is fascinated by ideas and can improve on what is existing